Search

Displaying results 2161 - 2170 of 5263 in total
  1. Drug

    Cipaglucosidase alfa

    go.drugbank.com/drugs/DB16708
    ApprovedInvestigational

    Cipaglucosidase alfa (ATB200) is a novel recombinant human acid alpha-glucosidase (GAA) investigated for the treatment of patients with Pompe disease, a rare inherited metabolic disorder characterized by … Cipaglucosidase alfa is conjugated with mannose-6-phosphate (M6P) N-glycans that bind to the cation-independent mannose-6-phosphate receptor (CI-MPR) in skeletal muscle, one of the main affected tissues

  2. Drug

    Osimertinib

    go.drugbank.com/drugs/DB09330
    ApprovedInvestigational

    Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals. … [A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved

    Synonyms: N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide
  3. Drug

    Benazepril

    go.drugbank.com/drugs/DB00542
    ApprovedInvestigational

    Upon cleavage of its ester group by the liver, benazepril is converted into its active form benazeprilat, a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor[A836].

  4. Drug

    Levobetaxolol

    go.drugbank.com/drugs/DB09351
    Approved

    It was marketed as a 0.5% ophthalmic solution of levobetaxolol hydrochloride under the trade name Betaxon but has been discontinued.

  5. Drug

    FT516

    go.drugbank.com/drugs/DB15732
    Investigational

    FT516 is an investigational and engineered off-the-shelf natural killer (NK) cell therapy originating from induced pluripotent stem cells (iPSC).

  6. Drug

    Olmesartan

    go.drugbank.com/drugs/DB00275
    ApprovedInvestigational

    ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and synthesis … [A175330] It was developed by Daiichi Sankyo Pharmaceuticals and approved in 2002.[A175345, L12882]

  7. Drug

    Tetrodotoxin

    go.drugbank.com/drugs/DB05232
    Investigational

    An aminoperhydroquinazoline poison found mainly in the liver and ovaries of fishes in the order tetraodontiformes, which are eaten. … Tetrodotoxin is being investigated by Wex Pharmaceuticals for the treatment of chronic and breakthrough pain in advanced cancer patients as well as for the treatment of opioid dependence.

  8. Target

    Immunoglobulin heavy constant alpha 2

    go.drugbank.com/bio_entities/BE0004610
    TargetHumans

    Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglo...

    Synonyms: Ig alpha-2 chain C region BUT
  9. Target

    Immunoglobulin heavy constant alpha 1

    go.drugbank.com/bio_entities/BE0005097
    TargetHumans

    Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglo...

    Synonyms: Ig alpha-1 chain C region BUR
  10. Drug

    Rilonacept

    go.drugbank.com/drugs/DB06372
    ApprovedInvestigational

    Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS...